Olema Oncology (Nasdaq: OLMA) announced preclinical AACR posters showing palazestrant fully recruits corepressor NCoR1 to achieve complete estrogen receptor antagonism and robust in vitro anti-tumor activity.
Data also show OP-3136, a KAT6 inhibitor, synergizes with palazestrant in ER+/HER2- models; palazestrant is in two Phase 3 trials and OP-3136 is enrolling in Phase 1. Posters presented April 20, 2026 at AACR.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.